Literature DB >> 8117353

Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.

E I Ette1, A W Kelman, C A Howie, B Whiting.   

Abstract

OBJECTIVE: To develop new approaches for evaluating results obtained from simulation studies used to determine sampling strategies for efficient estimation of population pharmacokinetic parameters.
METHODS: One-compartment kinetics with intravenous bolus injection was assumed and the simulated data (one observation made on each experimental unit [human subject or animal]), were analyzed using NONMEM. Several approaches were used to judge the efficiency of parameter estimation. These included: (1) individual and joint confidence intervals (CIs) coverage for parameter estimates that were computed in a manner that would reveal the influence of bias and standard error (SE) on interval estimates; (2) percent prediction error (%PE) approach; (3) the incidence of high pair-wise correlations; and (4) a design number approach. The design number (phi) is a new statistic that provides a composite measure of accuracy and precision (using SE).
RESULTS: The %PE approach is useful only in examining the efficiency of estimation of a parameter considered independently. The joint CI coverage approach permitted assessment of the accuracy and reliability of all model parameter estimates. The phi approach is an efficient method of achieving an accurate estimate of parameter(s) with good precision. Both the phi for individual parameter estimation and the overall phi for the estimation of model parameters led to optimal experimental design.
CONCLUSIONS: Application of these approaches to the analyses of the results of the study was found useful in determining the best sampling design (from a series of two sampling times designs within a study) for efficient estimation of population pharmacokinetic parameters.

Entities:  

Mesh:

Year:  1993        PMID: 8117353     DOI: 10.1177/106002809302700903

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  11 in total

1.  Designing population pharmacokinetic studies: performance of mixed designs.

Authors:  E O Fadiran; C D Jones; E I Ette
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

2.  Optimal design of a population pharmacodynamic experiment for ivabradine.

Authors:  S B Duffull; F Mentré; L Aarons
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

3.  Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.

Authors:  Marylore Chenel; Kayode Ogungbenro; Vincent Duval; Christian Laveille; Roeline Jochemsen; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

4.  Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Authors:  Stefan Wilde; Alexander Jetter; Stephan Rietbrock; Dirk Kasel; Andreas Engert; Andreas Josting; Beate Klimm; Georg Hempel; Stefanie Reif; Ulrich Jaehde; Ute Merkel; Dagmar Busse; Matthias Schwab; Volker Diehl; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Authors:  Marylore Chenel; François Bouzom; Leon Aarons; Kayode Ogungbenro
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-07       Impact factor: 2.745

6.  Analysis of animal pharmacokinetic data: performance of the one point per animal design.

Authors:  E I Ette; A W Kelman; C A Howie; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

7.  On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.

Authors:  H Sun; E I Ette; T M Ludden
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

8.  Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.

Authors:  Yewei Chen; Jinmiao Lu; Min Dong; Dan Wu; Yiqing Zhu; Qin Li; Chao Chen; Zhiping Li
Journal:  Eur J Clin Pharmacol       Date:  2016-09-19       Impact factor: 2.953

9.  Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.

Authors:  E I Ette; C A Howie; A W Kelman; B Whiting
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

10.  Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.

Authors:  Juliana F Roos; Carl M J Kirkpatrick; Susan E Tett; Andrew J McLachlan; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.